NCT04861415Recruiting
SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer
A Randomized Feasibility Trial of Stereotactic Body Radiotherapy Versus Conventional Fractionation With High Dose-rate (HDR) Brachytherapy Boost for Prostate Cancer
Source: ClinicalTrials.gov · Last updated 12 Apr 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Random assignment between SBRT and conventionally fractionated boost following HDR brachytherapy for prostate cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- First submitted
- 22 Apr 2021
- Start date
- 23 Dec 2020
- Primary completion date
- 23 Jun 2023
- Lead sponsor
- Dr. Gerard Morton
- Diseases
- Prostate cancer
- NCT number
- NCT04861415
What you commit to
- Study type: Interventional
- Planned participants: 55
- From 23 Dec 2020 to the primary completion date, 23 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Plan for adjuvant chemotherapy post-radiotherapy
Other illness
- Presence of nodal or distant metastasis on staging MRI or CT Abdomen/Pelvis and Bone scan within 90 days of enrolment (CT/MRI/Bone Scan are only required if the clinical risk of metastatic disease is sufficient to warrant these scans)
- Presence of inflammatory bowel disease
- Presence of connective tissue disorder seen as a contraindication to radiotherapy
Other
- Serious medical comorbidities or other contraindications to HDR brachytherapy
- Medically unfit for general/spinal anesthesia
- Unable or unwilling to complete questionnaires
Who the study is looking for
- Age 18 or older
- Informed consent for treatment and study participation completed
- Pathologically proven diagnosis of prostate adenocarcinoma
- ECOG Performance Status 0-2
- No prior history of pelvic radiotherapy, brachytherapy, cryosurgery, HIFU, TURP or radical prostatectomy
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sunnybrook Health Sciences Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.